Adaptimmune Therapeutics plc [ADAP] stock Initiated by Mizuho analyst, price target now $3

Adaptimmune Therapeutics plc [NASDAQ: ADAP] closed the trading session at $4.00 on 12/11/20. The day’s price range saw the stock hit a low of $3.79, while the highest price level was $4.11. The company report on November 20, 2020 that Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

– SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -.

– Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers -.

The stocks have a year to date performance of 233.33 percent and weekly performance of -10.51 percent. The stock has been moved at -61.65 percent over the last six months. The stock has performed -18.20 percent around the most recent 30 days and changed -57.54 percent over the most recent 3-months.

If compared to the average trading volume of 1.41M shares, ADAP reached to a volume of 4988992 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Adaptimmune Therapeutics plc [ADAP]:

Mizuho have made an estimate for Adaptimmune Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 22, 2020. The new note on the price target was released on August 02, 2019, representing the official price target for Adaptimmune Therapeutics plc stock.

The Average True Range (ATR) for Adaptimmune Therapeutics plc is set at 0.35, with the Price to Sales ratio for ADAP stock in the period of the last 12 months amounting to 195.91. The Price to Book ratio for the last quarter was 1.65, with the Price to Cash per share for the same quarter was set at 2.55.

ADAP stock trade performance evaluation

Adaptimmune Therapeutics plc [ADAP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.51. With this latest performance, ADAP shares dropped by -18.20% in over the last four-week period, additionally sinking by -61.65% over the last 6 months – not to mention a rise of 222.58% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 27.96, with the RSI for the last a single of trading hit 27.13, and the three-weeks RSI is set at 34.99 for Adaptimmune Therapeutics plc [ADAP]. The present Moving Average for the last 50 days of trading for this stock 5.51, while it was recorded at 4.22 for the last single week of trading, and 6.52 for the last 200 days.

Adaptimmune Therapeutics plc [ADAP]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Adaptimmune Therapeutics plc [ADAP] shares currently have an operating margin of -13713.28. Adaptimmune Therapeutics plc’s Net Margin is presently recorded at -12225.04.

Return on Total Capital for ADAP is now -78.03, given the latest momentum, and Return on Invested Capital for the company is -70.01. Return on Equity for this stock declined to -74.35, with Return on Assets sitting at -60.11. When it comes to the capital structure of this company, Adaptimmune Therapeutics plc [ADAP] has a Total Debt to Total Equity ratio set at 20.59. Additionally, ADAP Total Debt to Total Capital is recorded at 17.08, with Total Debt to Total Assets ending up at 14.02. Long-Term Debt to Equity for the company is recorded at 18.58, with the Long-Term Debt to Total Capital now at 15.40.

Reflecting on the efficiency of the workforce at the company, Adaptimmune Therapeutics plc [ADAP] managed to generate an average of -$344,332 per employee. Receivables Turnover for the company is 0.06 with a Total Asset Turnover recorded at a value of 0.00.Adaptimmune Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.20 and a Current Ratio set at 12.20.

Earnings per share (EPS) analysis for Adaptimmune Therapeutics plc [ADAP] stock

With the latest financial reports released by the company, Adaptimmune Therapeutics plc posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.34/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics plc go to 1.00%.

Adaptimmune Therapeutics plc [ADAP]: Insider Ownership positions

There are presently around $519 million, or 84.40% of ADAP stock, in the hands of institutional investors. The top three institutional holders of ADAP stocks are: MATRIX CAPITAL MANAGEMENT COMPANY, LP with ownership of 38,974,185, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 17,082,611 shares of the stock with an approximate value of $68.33 million in ADAP stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $45.32 million in ADAP stock with ownership of nearly -13.2% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Adaptimmune Therapeutics plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 46 institutional holders increased their position in Adaptimmune Therapeutics plc [NASDAQ:ADAP] by around 9,200,474 shares. Additionally, 39 investors decreased positions by around 7,531,604 shares, while 14 investors held positions by with 113,129,995 shares. The mentioned changes placed institutional holdings at 129,862,073 shares, according to the latest SEC report filing. ADAP stock had 24 new institutional investments in for a total of 2,035,888 shares, while 19 institutional investors sold positions of 3,552,690 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam